Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
50.91
+0.79 (+1.58%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
63
64
Next >
Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients
June 04, 2024
Opdivo plus Yervoy combo shows significant survival benefits and higher response rates vs. lenvatinib/sorafenib in HCC.
Via
Benzinga
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
June 04, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Bristol Myers Squibb
Via
Business Wire
6% Yield Bristol Myers Squibb Value Trap Or Long-Term Opportunity?
May 31, 2024
BMY is offering a 6% yield and trading for less than 9 times earnings.
Via
Talk Markets
Bristol-Myers Squibb's Options: A Look at What the Big Money is Thinking
May 30, 2024
Via
Benzinga
(BMY) - Analyzing Bristol-Myers Squibb's Short Interest
May 23, 2024
Via
Benzinga
Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday
June 03, 2024
Bristol Myers Squibb's KRYSTAL-12 study reveals Krazati's significant benefits over chemotherapy for KRASG12C-mutated NSCLC, improving progression-free survival and response rates.
Via
Benzinga
Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
June 03, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
June 03, 2024
From
Bristol Myers Squibb
Via
Business Wire
This Unpopular Dividend Stock Is a Buy
May 23, 2024
This top pharma stock has fallen too far.
Via
The Motley Fool
2 No-Brainer Dividend Stocks You Can Buy With $100 in June
June 03, 2024
This pair of high-yield dividend payers offer yields near 6% and a chance for steady payout raises in the years to come.
Via
The Motley Fool
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
June 01, 2024
From
Bristol Myers Squibb
Via
Business Wire
FDA Expands Approval For Bristol Myers Squibb's Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies
May 31, 2024
FDA approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) for relapsed or refractory mantle cell lymphoma, marking its fourth non-Hodgkin lymphoma subtype indication.
Via
Benzinga
Exposures
Product Safety
10 Health Care Stocks Whale Activity In Today's Session
May 31, 2024
Via
Benzinga
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
May 30, 2024
From
Bristol Myers Squibb
Via
Business Wire
7 Underappreciated Stocks With 25% Return Potential in 2024
May 30, 2024
Each of these underappreciated stocks is expected to provide 25%+ returns this year, which is reason enough to pay attention.
Via
InvestorPlace
Are Boomers Crashing The Economy Or Saving It? Why Investors Are Perplexed And What You Can Do To Prepare
May 29, 2024
Mass retirement of boomers could have major economic impact. Experts anticipate both risks and opportunities from the largest wealth transfer in history.
Via
Benzinga
Topics
Economy
Retirement
Exposures
Economy
Pension
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
May 29, 2024
From
Bristol Myers Squibb
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
May 28, 2024
Via
Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
May 28, 2024
Via
Benzinga
3 Blue-Chip Stocks to Buy at 52-Week Lows in May
May 27, 2024
These three blue-chip stocks at a 52-week low could provide investors with a good opportunity to open a new position or double an old one.
Via
InvestorPlace
S&P 500 Earnings Dashboard 24Q1 - Saturday, May 25
May 25, 2024
Of the 480 companies in the S&P 500 that have reported earnings to date for 24Q1, 77.9% reported above analyst expectations. This compares to a long-term average of 66%.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Retail Earnings & Consumer Spending: A Closer Look
May 25, 2024
The U.S. economy is chugging along, with growth moderately decelerating under the Fed’s tight monetary policy. Most of the Q1 earnings season is behind us, with results from 481 S&P 500 companies...
Via
Talk Markets
Topics
Economy
Stocks
Exposures
Economy
Interest Rates
US Equities
10 Health Care Stocks With Whale Alerts In Today's Session
May 24, 2024
Via
Benzinga
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
May 24, 2024
Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant...
Via
Benzinga
Exposures
Product Safety
Bonds Break Down And Send Everyone To Cash
May 23, 2024
This situation is where the danger, the opportunity, and the action are right now.
Via
Talk Markets
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
May 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
May 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M
May 22, 2024
A Hawaii judge has ordered Bristol Myers Squibb and Sanofi to pay $916 million for not warning non-white patients about the health risks of their blood thinner Plavix. The ruling follows a previous...
Via
Benzinga
Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
May 22, 2024
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
63
64
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.